What Is 1q21.1 deletion syndrome

Content on WhatAnswers is provided "as is" for informational purposes. While we strive for accuracy, we make no guarantees. Content is AI-assisted and should not be used as professional advice.

Last updated: April 15, 2026

Quick Answer: 1q21.1 deletion syndrome is a rare genetic disorder caused by the loss of a small segment of DNA on chromosome 1, specifically at band q21.1. It affects approximately 1 in 20,000 people and is associated with developmental delays, heart defects, and variable physical and neurological symptoms.

Key Facts

1q21.1 deletion syndrome affects about 1 in 20,000 individuals worldwide
The deletion occurs on the long arm (q) of chromosome 1 at position 21.1
Approximately 25% of affected individuals have congenital heart defects
Developmental delay is present in over 75% of diagnosed cases
The condition was first clinically described in 2008 in a study of 25 patients

Overview

1q21.1 deletion syndrome is a rare chromosomal disorder resulting from the deletion of a segment of DNA on the long arm of chromosome 1. This microdeletion spans approximately 1.0 to 1.5 megabases and typically includes several genes critical for normal development. The condition is highly variable in its presentation, with symptoms ranging from mild learning difficulties to severe congenital abnormalities.

Diagnosis is usually confirmed through chromosomal microarray analysis, which can detect small deletions not visible under a microscope. Because symptoms overlap with other neurodevelopmental disorders, 1q21.1 deletion syndrome is often underdiagnosed or misdiagnosed. Early detection can help guide medical management and support services.

Chromosome location: The deletion occurs at chromosome 1q21.1, involving a region spanning roughly 1.2 million base pairs and including at least 9 to 12 genes, such as GJA5 and GJA8.
Inheritance pattern: About 50% of cases are inherited from a parent, while the other half occur as de novo mutations with no family history of the condition.
Prevalence: Estimated to affect 1 in 20,000 individuals, though the actual number may be higher due to underdiagnosis and variable expressivity.
Common symptoms: Include developmental delay (seen in 75% of cases), mild facial dysmorphism, and motor coordination issues.
Associated conditions: Up to 25% of patients have congenital heart defects, particularly tetralogy of Fallot or atrial septal defects.

How It Works

The syndrome arises due to errors in chromosomal recombination during meiosis, leading to the loss of genetic material in a specific region of chromosome 1. This deletion disrupts the normal function of multiple genes, contributing to the wide range of clinical features observed.

Genes involved:GJA5, which encodes a gap junction protein, is linked to heart development, and its deletion may explain cardiac abnormalities in some patients.
Neurological impact: Loss of PRKAB2 and FMO5 may contribute to intellectual disability and autism spectrum traits observed in 30–40% of cases.
Copy number variation: The 1q21.1 region is prone to non-allelic homologous recombination, a mechanism that increases the risk of deletions and duplications.
Phenotypic variability: Even within families, individuals with the same deletion can show vastly different symptoms, from asymptomatic to severely affected.
Diagnostic tools: Chromosomal microarray (CMA) is the gold standard, detecting deletions as small as 100 kilobases with high accuracy.
Prenatal detection: The deletion can be identified prenatally via amniocentesis or chorionic villus sampling, especially if a parent is a known carrier.

Comparison at a Glance

Below is a comparison of 1q21.1 deletion syndrome with other common microdeletion syndromes based on prevalence, symptoms, and genetic mechanisms.

Syndrome	Chromosomal Location	Prevalence	Common Features	Inheritance Pattern
1q21.1 deletion	1q21.1	1 in 20,000	Developmental delay, heart defects, autism	50% inherited, 50% de novo
22q11.2 deletion (DiGeorge)	22q11.2	1 in 4,000	Heart defects, immune deficiency, cleft palate	90% de novo
Williams syndrome	7q11.23	1 in 7,500	Cardiovascular disease, elfin faces, hypersociability	Mostly de novo
Prader-Willi syndrome	15q11-q13	1 in 10,000	Obesity, hypotonia, hyperphagia	Deletion or imprinting defect
Smith-Magenis syndrome	17p11.2	1 in 15,000	Behavioral issues, sleep disturbances, short stature	Mostly de novo

This comparison highlights how 1q21.1 deletion syndrome is less common than other microdeletion disorders but shares overlapping features such as developmental delay and congenital anomalies. Unlike DiGeorge syndrome, which has a higher prevalence and more consistent phenotype, 1q21.1 deletion is notable for its extreme variability and incomplete penetrance, making clinical diagnosis more challenging.

Why It Matters

Understanding 1q21.1 deletion syndrome is crucial for improving diagnosis, genetic counseling, and patient care. As genetic testing becomes more accessible, more cases are being identified, emphasizing the need for awareness among healthcare providers.

Early intervention: Children with developmental delays benefit from early speech and occupational therapy, improving long-term outcomes.
Family planning: Genetic counseling helps families understand recurrence risks up to 50% if a parent carries the deletion.
Cardiac monitoring: Regular echocardiograms are recommended due to the 25% risk of heart defects.
Psychiatric support: Up to 40% of individuals may develop anxiety, ADHD, or schizophrenia-like symptoms requiring specialized care.
Research implications: Studying this region helps scientists understand the role of copy number variations in neurodevelopmental disorders.
Personalized medicine: As more data emerges, targeted therapies may one day address specific gene deficiencies caused by the deletion.

Continued research and patient registries are essential to fully understand the spectrum of 1q21.1 deletion syndrome and develop better support strategies for affected individuals and their families.